BiCKI-IL-7

**BiCKI-IL-7** is an investigational cancer immunotherapy from **OSE Immunotherapeutics** in preclinical development. It is a **bifunctional bispecific fusion protein** from the company's BiCKI platform that combines an **anti-PD-1 antibody backbone derived from OSE-279** with an **interleukin-7 payload**, creating a PD-1-targeted IL-7 immunocytokine-like biologic. The molecule is designed to bind **programmed cell death protein 1** on tumor-reactive T cells while delivering **IL-7 receptor pathway stimulation** to expand and reinvigorate effector and exhausted T-cell populations and reduce regulatory T-cell mediated immunosuppression, with the goal of overcoming resistance to anti-PD-1 or anti-P-L1 therapy. Available information indicates activity in **neoplasms** broadly, with preclinical reports of improved pharmacokinetics and antitumor efficacy versus anti-PD-1 antibody alone.

Other names

anti-PD-1xIL-7anti-PD1xIL-7anti-PD 1xIL-7bispecific anti-PD-1 x IL-7 fusion protein